ClinVar Miner

Submissions for variant NM_000090.4(COL3A1):c.2959G>A (p.Gly987Ser)

dbSNP: rs587779583
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV002310655 SCV000319284 pathogenic Familial thoracic aortic aneurysm and aortic dissection 2024-01-29 criteria provided, single submitter clinical testing The p.G987S pathogenic mutation (also known as c.2959G>A), located in coding exon 41 of the COL3A1 gene, results from a G to A substitution at nucleotide position 2959. The glycine at codon 987 is replaced by serine, an amino acid with similar properties. The majority (approximately two-thirds) of COL3A1 mutations identified to date have involved the substitution of another amino acid for glycine within the triple-helical domain (Pepin MG et al. Genet Med. 2014;16(12):881-8; Frank M et al. Eur J Hum Genet. 2015;23(12):1657-64). This particular glycine substitution has been detected in two vascular Ehlers-Danlos syndrome (EDS) cohorts and has been reported as a likely de novo alteration in a patient with features consistent with EDS (Pepin MG et al. Genet Med. 2014;16(12):881-8; Frank M et al. Eur J Hum Genet. 2015;23(12):1657-64; Lan NSR et al. Cardiovasc. Pathol. 2018;35:48-51). Internal structural analysis has demonstrated that this alteration disrupts the characteristic G-X-Y motif in the COL3A1 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7; Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne RCV000087534 SCV000966168 pathogenic Ehlers-Danlos syndrome, type 4 2018-10-19 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000087534 SCV001225507 pathogenic Ehlers-Danlos syndrome, type 4 2023-07-28 criteria provided, single submitter clinical testing Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL3A1 protein function. ClinVar contains an entry for this variant (Variation ID: 101296). This missense change has been observed in individual(s) with clinical features of Ehlers-Danlos syndrome (PMID: 24922459, 25758994, 29778910). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 987 of the COL3A1 protein (p.Gly987Ser). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly987 amino acid residue in COL3A1. Other variant(s) that disrupt this residue have been observed in individuals with COL3A1-related conditions (PMID: 25758994), which suggests that this may be a clinically significant amino acid residue. This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC).
Collagen Diagnostic Laboratory, University of Washington RCV000087534 SCV000120421 pathogenic Ehlers-Danlos syndrome, type 4 no assertion criteria provided clinical testing
GenomeConnect - Invitae Patient Insights Network RCV000087534 SCV001749372 not provided Ehlers-Danlos syndrome, type 4 no assertion provided phenotyping only Variant interpreted as Pathogenic and reported on 01-30-2019 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.